Screen for Life. Breathe with Hope.
In 2015, the United Nations (UN) adopted 17 Sustainable Development Goals. Goal 3 and 4 aim to reduce premature deaths from noncommunicable diseases, including cancer, by one third by 20301.
With lung cancer being one of the leading causes of cancer death, Canon Medical, under our Made for Life philosophy, is committed to improve patient outcomes by supporting healthcare professionals and eligible patients along their journey with our advanced imaging solutions that facilitate reliable and seamless screening.
Through the "Screen for Life. Breathe with Hope." initiative, we aim to change societal perceptions of lung cancer and encourage participation in early screening, which would ultimately contribute to the reduction of cancer mortality. Collaborating with experts in this discipline, we will provide comprehensive information to help healthcare professionals address the needs of the prospective participants.
Subscribe to our newsletter to receive updates on our educational events and scientific information.
Educational Events
Perspectives Webinar: Unlocking Access to Lung Cancer Screening
Join us for a roundtable discussion with leading clinical experts, to explore how lung cancer screening implementation and uptake among eligible patients can be improved.
Learn about the webinar and register now
Stories of Inspiration
Detecting Cancer Earlier With AI
After radiologist Prof. Marie-Pierre Revel lost her cousin to lung cancer, a screening helped to catch her own cancer early. Watch a film produced by BBC StoryWorks and discover the impact improved imaging is having on potentially life- saving CT scans, helping shape a new standard in lung cancer detection.
Please accept marketing-cookies to watch this video.
Subscribe to our newsletter to receive updates on our educational events and scientific information.
Lung Cancer Screening
Early detection to save more lives
Lung cancer is one of the most frequent causes of cancer and the leading cause of cancer death globally2 . When patients present with symptoms, the disease often has already progressed, with limited options remaining for treatment. As a result, prognosis in lung cancer tends to be poor, despite advances in treatment. However, when the disease is detected at an early stage, the chances of survival increase dramatically3.
Consequently, there is a growing interest in lung cancer screening worldwide as the main opportunity to reduce lung cancer mortality.
Consequently, there is a growing interest in lung cancer screening worldwide as the main opportunity to reduce lung cancer mortality.
Canon Medical aims to be your partner in the fight against lung cancer and offers a unique set of lung cancer screening solutions. These include a suite of innovative technologies to enhance your clinical confidence everywhere, delivering high-quality imaging at low dose, streamlining workflows, and offering comprehensive diagnosis throughout the entire cycle of care.
"You only have a chance and a good outcome if you detect the cancer at a very, very early stage. And that is the purpose of lung cancer screening."
Prof. Cornelia M Schaefer- Prokop, MD, PhD
Radiologist
Appointed member of the Fleischner Society (international group of lung specialists)
Former president of the European Society of Thoracic Imaging (ESTI)
Meander Medical Centre, Amersfoort
Radboud University Medical Center (Radboudumc), Nijmegen the Netherlands
Prof. Cornelia M Schaefer- Prokop, MD, PhD
Radiologist
Appointed member of the Fleischner Society (international group of lung specialists)
Former president of the European Society of Thoracic Imaging (ESTI)
Meander Medical Centre, Amersfoort
Radboud University Medical Center (Radboudumc), Nijmegen the Netherlands
Please accept marketing-cookies to watch this video.
Lung cancer is the leading cause of cancer related death worldwide and the second most commonly diagnosed cancer.
Early detection of lung cancer increases the chances of survival. The majority of patients with late detection (stage IV) die within 5 years while patients with lung cancer detected in an early stage (stage 1A) have a higher chance of survival, over 5 years.
Earlier detection through screening programs could significantly improve patient outcomes. In high-risk individuals, the risk of dying of lung cancer is reduced by 20% for men. In women, the reduction in lung cancer mortality may be even higher.
As patients can be treated earlier, screening for lung cancer has the potential to reduce costs. However, the extent of savings heavily depends on how screening programs are implemented.
Current challenges
Lung cancer screening faces various challenges that hinder its widespread success.
As part of our Made for Life philosophy, Canon Medical is committed to providing support to address these challenges.
As part of our Made for Life philosophy, Canon Medical is committed to providing support to address these challenges.
Challenge 1: Low participation rate
Many individuals at high risk for lung cancer are often unaware of the potential benefits of screening or may face barriers such as cost, accessibility, or fear of the screening process.
Challenge 2: Workload and workflow
Workflow issues, such as managing the influx of screening participants and ensuring timely communication of results, can be a significant burden. Moreover, the repetitive nature of interpreting numerous lung scans can be mentally draining and lead to a loss of enthusiasm.
Challenge 3: Maintain clinical confidence at low dose
Screening participants are typically exposed to repeated CT scans which raises concerns around radiation dose. Lung cancer screening when performed without efficient CT hardware and image reconstruction algorithms, may yield inconclusive or false positive results, leading to additional and costly follow-up procedures, while causing anxiety and stress for patients.
Challenge 4: Cost-effectiveness
Cost-effectiveness of the program requires a careful balance of the investments in equipment and staff, training, and the number of diagnostic and downstream follow-up procedures versus the benefits of improved health outcomes and less spending on costly therapies in the long-run.
Our solutions
We are taking measures to increase the accessibility of lung cancer screening for the public, providing high-quality imaging at low dose, removing workflow inefficiencies, supporting the interpretation and communication of findings among clinicians, and streamlining follow-up procedures.
Together, we can improve the patient experience and ensure a high-quality and cost-effective screening program, while minimizing the burden of the lung cancer on patients worldwide.
Together, we can improve the patient experience and ensure a high-quality and cost-effective screening program, while minimizing the burden of the lung cancer on patients worldwide.
Easy access to screening
Our Mobile Imaging Solutions allow you to conveniently perform scans, expanding accessibility and bringing the screening experience closer to your patients.
Efficient workflow
Our new workflow experience, INSTINX optimizes efficiency, ensuring quick and seamless CT scans.
High-quality images at low dose
Our AI-enhanced CT lung cancer screening solutions, including the combination of SilverBeam filter and AiCE offer high-quality images with minimal noise and radiation exposure.
Risk stratification and diagnosis
Our Vitrea Advanced Visualization lung cancer screening solution automatically detects lung nodules, enables comprehensive lung analysis and supports faster and more efficient diagnosis.
Easy access to screening
Easy access from anywhere
One of the main challenges of lung cancer screening is reaching the people who may need it the most. Mobile imaging solutions allow you to provide healthcare and education where people live and work, and offer screening close to their homes. By removing barriers to access, mobile imaging services may play a significant role in improving lung cancer screening rates and contribute to more equitable healthcare. The design of our mobile medical equipment provides a comfortable and convenient environment for high-patient throughput lung cancer screening without any compromises on patient safety, workflow or image quality.
"Developing a mobile program allowed delivery of healthcare to rural parts of our state with the ultimate goal of mitigating some of the cancer outcome disparities of our state and region."
Prof. Hannah Hazard- Jenkins, MD, FACS
Associate Professor of Surgery at the department of Surgery WVU School of Medicine
Director of the WVU Cancer Institute
Morgantown, West Virginia, USA
Prof. Hannah Hazard- Jenkins, MD, FACS
Associate Professor of Surgery at the department of Surgery WVU School of Medicine
Director of the WVU Cancer Institute
Morgantown, West Virginia, USA
Please accept marketing-cookies to watch this video.
Efficient workflow
Scanning is easier than ever before
An efficient workflow is essential for lung cancer screening. It enhances accessibility, reduces waiting times, optimizes resource utilization, and improves overall patient care. By prioritizing efficiency, we provide patient-centric end-to-end workflow solutions, incorporating intuitive design and automated features for improved efficiency through the INSTINX workflow.
INSTINX workflow
Canon's CT total workflow experience is redesigned from the ground up to set new standards in efficiency and consistency. Every detail of the workflow has been thoroughly refined and validated through clinical testing in medical centers around the world.
Canon's CT total workflow experience is redesigned from the ground up to set new standards in efficiency and consistency. Every detail of the workflow has been thoroughly refined and validated through clinical testing in medical centers around the world.
Automatic scan planning for all chest routine scans
INSTINX features automatic scan planning to automatically plan all routine scans including scan ranges and parameters, including dose and exposure settings, using the unique 3D Landmark Scan data and Anatomical Landmark Detection technology.
INSTINX features automatic scan planning to automatically plan all routine scans including scan ranges and parameters, including dose and exposure settings, using the unique 3D Landmark Scan data and Anatomical Landmark Detection technology.
High-quality images at low dose
A unique synergy of beam filtering and AI-enhanced reconstruction technologies
Lung cancer screening demands high patient throughput and low radiation dose while providing images that have the quality for a reliable assessment of nodule growth and malignancy. The unique combination of SilverBeam Filter with our specific Deep Learning imaging reconstruction results in the best possible image quality at typical lung cancer screening doses.
SilverBeam Filter
SilverBeam, a beam shaping energy filter, leverages the photon-attenuating properties of silver to selectively remove low energy photons from a polychromatic X-ray beam, leaving an energy spectrum optimized for lung cancer screening.
SilverBeam, a beam shaping energy filter, leverages the photon-attenuating properties of silver to selectively remove low energy photons from a polychromatic X-ray beam, leaving an energy spectrum optimized for lung cancer screening.
Advanced intelligent Clear-IQ Engine (AiCE)
AiCE is an innovative Deep Learning Reconstruction technology that has been trained to reduce noise and boost signal to deliver sharp, clear and distinct images at speed.
AiCE is an innovative Deep Learning Reconstruction technology that has been trained to reduce noise and boost signal to deliver sharp, clear and distinct images at speed.
✓ Low Noise
✓ Natural Image Texture*1
✓ Twice the high contrast spatial resolution*2
✓ Clear Low Contrast Detectability
✓ Reduced dose for body imaging*3
*1 Natural defined as similar to FBP compared to MBIR
*2 AiCE Body Sharp compared to AIDR 3D Body Sharp at 10% MTF measured using the Teflon sensitometry module of Catphan600
*3 Compared to FBP
✓ Natural Image Texture*1
✓ Twice the high contrast spatial resolution*2
✓ Clear Low Contrast Detectability
✓ Reduced dose for body imaging*3
*1 Natural defined as similar to FBP compared to MBIR
*2 AiCE Body Sharp compared to AIDR 3D Body Sharp at 10% MTF measured using the Teflon sensitometry module of Catphan600
*3 Compared to FBP
Small lung nodule detection
High-quality lung CT imaging at 0.54 mSv utilizing the combination of SilverBeam Filter and AiCE.
In this patient, a small lung nodule is clearly visible in the upper right lobe.
Courtesy of Fujita Health University Hospital, Japan
More detail in comparison to X-ray
In contrast to the chest X-ray, the presence of lung cancer is clearly visible in the left upper lobe. Utilizing the combination of SilverBeam Filter and AiCE, the effective dose of this scan was only 0.18 mSv, a dose level closer to a chest X-ray3
Courtesy of Dr. Russell Bull, Royal Bournemouth Hospital, Bournemouth, UK
Follow-up imaging at low dose
SilverBeam Filter combined with AiCE delivers high-quality images of the lungs at a dose closer to a chest X-ray.
In this patient, 94% dose reduction was achieved at follow-up through the implementation of our SilverBeam Filter as compared to the initial scan using a standard filter, while nodule conspicuity was maintained.
Courtesy NHLBI, National Institutes of Health, USA
"I have had patients who are reluctant to come in for a chest CT because of the fears of radiation. However, with Canon Medical technology, that barrier is removed. And now, we are able to offer ultra-low dose chest CT for screening for lung cancer, and that's a game changer."
Dr. Marcus Chen
Director of Cardiothoracic Imaging at the National
Institutes for Health (NIH), Maryland, US
Dr. Marcus Chen
Director of Cardiothoracic Imaging at the National
Institutes for Health (NIH), Maryland, US
Please accept marketing-cookies to watch this video.
Risk stratification and diagnosis
Standardized lung nodule assessment and comprehensive characterization of nodules over time
A key aspect of any lung cancer screening program is the accurate and timely reporting of scans followed by streamlined nodule management and lung disease management. However, without appropriate software solutions, the reporting of lung cancer examinations can be a time- consuming task that is prone to error.
The comprehensive lung cancer screening solution in Vitrea Advanced Visualization contains automated tools that support you in the detection and characterization of different lung nodule types including the assessment of growth patterns. To facilitate workflow and structured reporting, findings are automatically transferred to your reporting template with quick reference to guidelines such as Lung-RADS and the Fleischner Criteria.
The comprehensive lung cancer screening solution in Vitrea Advanced Visualization contains automated tools that support you in the detection and characterization of different lung nodule types including the assessment of growth patterns. To facilitate workflow and structured reporting, findings are automatically transferred to your reporting template with quick reference to guidelines such as Lung-RADS and the Fleischner Criteria.
Automatically detects potentially actionable lung nodules and quantitative assessment of growth.
Clinical Evidence
Customer Presentations
Watch our speakers present the latest developments in lung cancer screening, give advice on how to overcome barriers in clinical implementation and improve access to screening and share the newest technology in ultra-low dose CT.
White Papers and Case Studies
Download our latest white papers and case studies on lung cancer screening solutions using Canon technologies here.
Scientific Papers
Find our latest scientific evidence on lung cancer screening solutions using Canon technologies here.
Yanagawa, M et al. | Lung adenocarcinoma at CT with 0.25- mm section thickness and a 2048 matrix: high-spatial-resolution imaging for predicting invasiveness |Radiology (2020)
Tsubamoto, M et al. | Ultra high-resolution computed tomography with 1024-matrix: Comparison with 512-matrix for the evaluation of pulmonary nodules. |European Journal of Radiology (2020)
Lucia J M Kroft et al. | Added Value of Ultra-Low-Dose Computed Tomography, Dose Equivalent to Chest x-Ray Radiography, for Diagnosing Chest Pathology | J Thorac Imaging (2019)
Fujita, M et al. | Lung cancer screening with ultra-low dose CT using full iterative reconstruction | Japanese journal of radiology (2017)
Meyer, E. et al. | Wide-volume versus helical acquisition in unenhanced chest CT: prospective intra-patient comparison of diagnostic accuracy and radiation dose in an ultra- low-dose setting |European Radiology (2019)
Schaal, M. et al. | Diagnostic Performance of Ultra-Low-Dose Computed Tomography for Detecting Asbestos-Related Pleuropulmonary Diseases: Prospective Study in a Screening Setting| PLOS One (2016)
Kakinuma R et al. | Ultra-High-Resolution Computed Tomography of the Lung: Image Quality of a Prototype Scanner | PLoS ONE (2015)
Nomura, Y et al. | Effects of iterative reconstruction algorithms on computer-assisted detection (CAD) software for lung nodules in ultra- low- dose CT for lung cancer screening |Academic Radiology (2017)
General references
4. RadiologyInfo.org | Radiation Dose from X-Ray and CT Exams | RadiologyInfo.org. (2022)
Due to medical device regulatory reasons, not all products/services displayed on this Canon Medical Systems webpage are available in all countries or markets. Future availability of the products/service cannot also be guaranteed. Don't hesitate to contact your local Canon Medical Systems representative for further details.
